Medivir AB (publ)
MVRBF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $4 | $26 | $14 | $9 |
| % Growth | -82.7% | 83.1% | 59.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $4 | $26 | $14 | $9 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $73 | $53 | $91 |
| SG&A Expenses | $0 | $73 | $53 | $91 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $10 | $0 |
| Operating Expenses | $93 | $90 | $70 | $135 |
| Operating Income | -$87 | -$62 | -$43 | -$126 |
| % Margin | -1,981.7% | -243.2% | -307.6% | -1,444.1% |
| Other Income/Exp. Net | -$1 | -$0 | $0 | $3 |
| Pre-Tax Income | -$89 | -$63 | -$43 | -$123 |
| Tax Expense | $0 | $1 | $0 | $0 |
| Net Income | -$89 | -$63 | -$43 | -$123 |
| % Margin | -2,013.7% | -247.2% | -305.6% | -1,414.9% |
| EPS | -1.59 | -1.2 | -1.44 | -4.17 |
| % Growth | -32.5% | 16.7% | 65.5% | – |
| EPS Diluted | -1.59 | -1.2 | -1.44 | -4.17 |
| Weighted Avg Shares Out | 56 | 53 | 30 | 30 |
| Weighted Avg Shares Out Dil | 56 | 53 | 30 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $3 | $3 | $4 | $7 |
| EBITDA | -$85 | -$59 | -$38 | -$115 |
| % Margin | -1,934.3% | -231.2% | -269.9% | -1,317.4% |